During the period from 2018 to 2020, the Ukrainian pharmaceutical company “Darnitsa” completed 8 studies of generics – bioequivalent drugs to treat diseases of the heart and central nervous system. Most of the work was done in Ukraine and the final stages of testing were carried out in European laboratories. The research centers of the European Union were to confirm the therapeutic equivalence and safety of medicines developed by ZAO Darnitsa.
Commenting on the completion of the trials, Dmytro Shymkiv, the chairman of the board of directors of the pharmaceutical concern Darnitsa Group, said that the responsibility to patients comes first for the company. That was the reason why during the development and testing of medicines it was decided to cooperate with European laboratories. They conducted bioanalytical research. Experts from the EU have confirmed that Ukrainian generics are fully consistent with the original drugs in terms of their effectiveness, safety and patient tolerance.
Dmytro Shymkiv emphasized that when choosing a partner laboratory the pharmaceutical company “Darnitsa” was guided by the main requirement – the ability to ensure a high level of research quality in accordance with international requirements. In order to qualify, the bioanalytical center must have high-tech equipment, a sufficient number of specialists and an impeccable reputation. One of these laboratories is the Czech QUINTA-ANALYTICA s.r.o. It is an innovative, dynamic and trusted global leader in pharmaceutical analysis, drug research, development and clinical trials. Darnitsa Group has been cooperating with it for several years, so the management of Darnitsa is absolutely confident that the research results are trustworthy.
According to Dmytro Shymkiv, such a productive interaction of Ukrainian and European specialists makes it possible to achieve the maximum quality of domestic medicines and timely delivery of medicines to the market. Thanks to the cooperation between Darnitsa and European bioanalytical centers Ukrainians have an opportunity to purchase effective and safe analogues of expensive drugs at affordable price.